Abstract 1178P
Background
Melanoma is the fifth most common cancer and, although rare, is the most common skin malignancy in those under 20 years old in the United States (US), with an average annual incidence rate (IR) of 5.5-6.0 cases per million. Since the 1970s, the incidence of pediatric melanoma has increased with an average annual percent change of 2–2.9% in the US. Epidemiological knowledge and predictors of melanoma among children and adolescents (age < 20 years) in Korea are limited.
Methods
Using data from National Health Insurance (NHI) database, we identified incident melanoma cases diagnosed at 0-19 years old during 2004-2019 in Korea, respectively. Using a joinpoint regression model, associations between demographic factors and melanoma incidence rates (IR) were evaluated by calculating incidence rate ratios and 95% confidence intervals (CI).
Results
We identified a total of 1160 patients (age < 20 years) with cutaneous malignant melanoma from 2004-2019. The overall average annual melanoma incidence was 0.22 per million (95% CI, 0.21-0.23) in Korea. It increased with age (age 0-4: 0.3, age 5-9: 0.6, age 10-14: 0.6, age 15-19: 07 per 100,000 persons) but there was no difference in IR according to sex. The age-adjusted incidence of melanoma decreased 4.5% yearly from 2004 to 2012 (95% CI, -8.9%–0.1%) but increased 12.6% yearly from 2012 to 2019 (95% CI, 5.9%–19.6%). A strong correlation between melanoma IR and nevi was confirmed (OR 85.4, 95% CI 67.97 - 106.40, P < 0.001) and this was also linked to the survival rate (5-year survival rate: 97.7% vs 91.9%, P = 0.044).
Conclusions
Although the incidence of melanoma in children and adolescent is very low, it is clear that it increases in Korea. To our knowledge, this is the first report to suggest that melanoma IR trends in children and adolescent are annually increasing in Korea. Most importantly, we must increase awareness and education amongst pediatricians, internists and the general population with regard to prevention and early diagnosis of melanoma for both children and adults. In addition, the physicians should include a complete skin examination for children with congenital nevi.
Clinical trial identification
none
Editorial acknowledgement
none
Legal entity responsible for the study
Jisu Oh.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1181TiP - BEPCOME-MB: Treatment of BRAFV600 mutated melanoma brain metastases with encorafenib + binimetinb + pembrolizumab with or without stereotactic radiosurgery
Presenter: Philippe Saiag
Session: Poster session 13
1188P - Landscape of Delta-like-ligand 3 (DLL3) expression across neuroendocrine neoplasms (NENs)
Presenter: Anthony Crymes
Session: Poster session 13
1189P - Mixed neuroendocrine-non neuroendocrine neoplasms (MiNEN): Characterization of the genomic and pathological profile
Presenter: Annabella Di Mauro
Session: Poster session 13
1191P - TTF-1 expression in lung neuroendocrine tumors (NET): A gender-related biomarker
Presenter: Anna La Salvia
Session: Poster session 13
1192P - Smoking adversely affects survival of metastatic lung carcinoid patients: Analysis of a large international audit
Presenter: Sara Valpione
Session: Poster session 13
1193P - Evaluation of treatment appropriateness in patients submitted to surgery for non-functioning pancreatic neuroendocrine tumors (NF-PanNETs)
Presenter: Anna Battistella
Session: Poster session 13
1194P - Do metastatic appendiceal NETs ever develop metachronously after appendectomy or right hemicolectomy?
Presenter: Taymeyah Al-Toubah
Session: Poster session 13
1195P - Neuroendocrine Tumors (NETs): How Big Data (BD) techniques applied to Electronic Health Records (EHR) can improve our understanding of this patient population
Presenter: Jorge Hernando
Session: Poster session 13
1196P - Regional lymph node metastasis risk factors for rectal neuroendocrine tumors: A population-based study
Presenter: Dan Cao
Session: Poster session 13
1197P - Somatostatin analogs or active surveillance in sporadic non-functioning pancreatic neuroendocrine tumors
Presenter: Maria Grazia Maratta
Session: Poster session 13